CP-189 Infliximab biosimilar: Cost-efficacy analysis

Background

The biosimilar medicines are identical to authorised biological medicines. The biosimilar infliximab, a TNF-α inhibitor, was approved by the EMA for use in rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis. Studies have shown that the biosimilar of infliximab demonstrates pharmacokinetics and therapeutic equivalence relative to its reference, with lower costs,...